{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:43:47Z","timestamp":1787168627734,"version":"build-2736575974"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T00:00:00Z","timestamp":1575504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T00:00:00Z","timestamp":1575504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001843","name":"DST | Science and Engineering Research Board","doi-asserted-by":"publisher","award":["EMR\/2016\/005008"],"award-info":[{"award-number":["EMR\/2016\/005008"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The improvement of body\u2019s own immune system is considered one of the safest approaches to fight against cancer and several other diseases. Excessive catabolism of the essential amino acid, L-tryptophan (L-Trp) assists the cancer cells to escape normal immune obliteration. The formation of disproportionate kynurenine and other downstream metabolites suppress the T cell functions. Blocking of this immunosuppressive mechanism is considered as a promising approach against cancer, neurological disorders, autoimmunity, and other immune-mediated diseases. Overexpression of indoleamine 2,3-dioxygenase 1 (IDO1) enzyme is directly related to the induction of immunosuppressive mechanisms and represents an important therapeutic target. Several classes of small molecule-based IDO1 inhibitors have been already reported, but only few compounds are currently being evaluated in various stages of clinical trials as adjuvants or in combination with chemo- and radiotherapies. In the quest for novel structural class(s) of IDO1 inhibitors, we developed a series of 4,5-disubstituted 1,2,3-triazole derivatives. The optimization of 4,5-disubstituted 1,2,3-triazole scaffold and comprehensive biochemical and biophysical studies led to the identification of compounds,\n                    <jats:bold>3i<\/jats:bold>\n                    ,\n                    <jats:bold>4i<\/jats:bold>\n                    , and\n                    <jats:bold>4k<\/jats:bold>\n                    as potent and selective inhibitors of IDO1 enzyme with IC\n                    <jats:sub>50<\/jats:sub>\n                    values at a low nanomolar level. These potent compounds also showed strong IDO1 inhibitory activities in MDA-MB-231 cells with no\/negligible level of cytotoxicity. The T cell activity studies revealed that controlled regulation of IDO1 enzyme activity in the presence of these potent compounds could induce immune response against breast cancer cells. The compounds also showed excellent\n                    <jats:italic>in vivo<\/jats:italic>\n                    antitumor efficacy (of tumor growth inhibition = 79\u201396%) in the female Swiss albino mice. As a consequence, this study describes the first example of 4,5-disubstituted 1,2,3-triazole based IDO1 inhibitors with potential applications for immunotherapeutic studies.\n                  <\/jats:p>","DOI":"10.1038\/s41598-019-54963-9","type":"journal-article","created":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T06:02:42Z","timestamp":1575525762000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["4,5-Disubstituted 1,2,3-triazoles: Effective Inhibition of Indoleamine 2,3-Dioxygenase 1 Enzyme Regulates T cell Activity and Mitigates Tumor Growth"],"prefix":"10.1038","volume":"9","author":[{"given":"Subhankar","family":"Panda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirmalya","family":"Pradhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumya","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhir","family":"Morla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashalata","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arindam","family":"Bhattacharyya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6920-9000","authenticated-orcid":false,"given":"Debasis","family":"Manna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,5]]},"reference":[{"key":"54963_CR1","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nrd4591","volume":"14","author":"KM Mahoney","year":"2015","unstructured":"Mahoney, K. M., Rennert, P. D. & Freeman, G. J. Combination cancer immunotherapy and new immunomodulatory targets. Nat. Rev. Drug Discov. 14, 561\u2013584 (2015).","journal-title":"Nat. Rev. Drug Discov."},{"key":"54963_CR2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.immuni.2004.07.017","volume":"21","author":"GP Dunn","year":"2004","unstructured":"Dunn, G. P., Old, L. J. & Schreiber, R. D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21, 137\u2013148 (2004).","journal-title":"Immunity"},{"key":"54963_CR3","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1038\/cti.2014.7","volume":"3","author":"MH Kershaw","year":"2014","unstructured":"Kershaw, M. H., Westwood, J. A., Slaney, C. Y. & Darcy, P. K. Clinical application of genetically modified T cells in cancer therapy. Clin. Transl. Immunol. 3, e16 (2014).","journal-title":"Clin. Transl. Immunol."},{"key":"54963_CR4","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/nrc1586","volume":"5","author":"WP Zou","year":"2005","unstructured":"Zou, W. P. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5, 263\u2013274 (2005).","journal-title":"Nat. Rev. Cancer"},{"key":"54963_CR5","doi-asserted-by":"publisher","first-page":"7575","DOI":"10.1039\/C5RA25046C","volume":"6","author":"S Qian","year":"2016","unstructured":"Qian, S. et al. IDO as a drug target for cancer immunotherapy: recent developments in IDO inhibitors discovery. Rsc Adv. 6, 7575\u20137581 (2016).","journal-title":"Rsc Adv."},{"key":"54963_CR6","doi-asserted-by":"publisher","first-page":"6030","DOI":"10.1158\/1078-0432.CCR-04-2671","volume":"11","author":"A Okamoto","year":"2005","unstructured":"Okamoto, A. et al. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin. Cancer Res. 11, 6030\u20136039 (2005).","journal-title":"Clin. Cancer Res."},{"key":"54963_CR7","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/nm934","volume":"9","author":"C Uyttenhove","year":"2003","unstructured":"Uyttenhove, C. et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9, 1269\u20131274 (2003).","journal-title":"Nat. Med."},{"key":"54963_CR8","doi-asserted-by":"publisher","first-page":"9421","DOI":"10.1021\/acs.jmedchem.5b00326","volume":"58","author":"UF Rohrig","year":"2015","unstructured":"Rohrig, U. F., Majjigapu, S. R., Vogel, P., Zoete, V. & Michielin, O. Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors. J. Med. Chem. 58, 9421\u20139437 (2015).","journal-title":"J. Med. Chem."},{"key":"54963_CR9","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1172\/JCI31178","volume":"117","author":"DH Munn","year":"2007","unstructured":"Munn, D. H. & Mellor, A. L. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J. Clin. Investig. 117, 1147\u20131154 (2007).","journal-title":"J. Clin. Investig."},{"key":"54963_CR10","doi-asserted-by":"crossref","unstructured":"van Baren, N. & Van den Eynde, B. J. Tryptophan-degrading enzymes in tumoral immune resistance. Front. Immunol. 6 (2015).","DOI":"10.3389\/fimmu.2015.00034"},{"key":"54963_CR11","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1158\/0008-5472.CAN-06-2925","volume":"67","author":"DY Hou","year":"2007","unstructured":"Hou, D. Y. et al. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res. 67, 792\u2013801 (2007).","journal-title":"Cancer Res."},{"key":"54963_CR12","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/nm1196","volume":"11","author":"AJ Muller","year":"2005","unstructured":"Muller, A. J., DuHadaway, J. B., Donover, P. S., Sutanto-Ward, E. & Prendergast, G. C. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat. Med. 11, 312\u2013319 (2005).","journal-title":"Nat. Med."},{"key":"54963_CR13","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1158\/1535-7163.MCT-09-0628","volume":"9","author":"HK Koblish","year":"2010","unstructured":"Koblish, H. K. et al. Hydroxyamidine Inhibitors of Indoleamine-2,3-dioxygenase Potently Suppress Systemic Tryptophan Catabolism and the Growth of IDO-Expressing Tumors. Mol. Cancer Ther. 9, 489\u2013498 (2010).","journal-title":"Mol. Cancer Ther."},{"key":"54963_CR14","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1158\/2159-8290.CD-12-0014","volume":"2","author":"C Smith","year":"2012","unstructured":"Smith, C. et al. IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development. Cancer Discov. 2, 722\u2013735 (2012).","journal-title":"Cancer Discov."},{"key":"54963_CR15","doi-asserted-by":"crossref","unstructured":"Favre, D. et al. Tryptophan Catabolism by Indoleamine 2,3-Dioxygenase 1 Alters the Balance of T(H)17 to Regulatory T Cells in HIV Disease. Sci. Transl. Med. 2 (2010).","DOI":"10.1126\/scitranslmed.3000632"},{"key":"54963_CR16","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3233\/JAD-140414","volume":"43","author":"D Yu","year":"2015","unstructured":"Yu, D. et al. The IDO Inhibitor Coptisine Ameliorates Cognitive Impairment in a Mouse Model of Alzheimer\u2019s Disease. J. Alzheimers Dis. 43, 291\u2013302 (2015).","journal-title":"J. Alzheimers Dis."},{"key":"54963_CR17","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1182\/blood-2005-04-1403","volume":"106","author":"R Potula","year":"2005","unstructured":"Potula, R. et al. Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis. Blood 106, 2382\u20132390 (2005).","journal-title":"Blood"},{"key":"54963_CR18","doi-asserted-by":"publisher","first-page":"5680","DOI":"10.1016\/j.ejmech.2011.08.044","volume":"46","author":"Q Huang","year":"2011","unstructured":"Huang, Q. et al. Structure-activity relationship and enzyme kinetic studies on 4-aryl-1H-1,2, 3-triazoles as indoleamine 2,3-dioxygenase (IDO) inhibitors. Eur. J. Med. Chem. 46, 5680\u20135687 (2011).","journal-title":"Eur. J. Med. Chem."},{"key":"54963_CR19","doi-asserted-by":"publisher","first-page":"5270","DOI":"10.1021\/jm300260v","volume":"55","author":"UF Rohrig","year":"2012","unstructured":"Rohrig, U. F. et al. Rational design of 4-aryl-1,2,3-triazoles for indoleamine 2,3-dioxygenase 1 inhibition. J. Med. Chem. 55, 5270\u20135290 (2012).","journal-title":"J. Med. Chem."},{"key":"54963_CR20","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1021\/acs.orglett.7b00313","volume":"19","author":"S Panda","year":"2017","unstructured":"Panda, S., Maity, P. & Manna, D. Transition Metal, Azide, and Oxidant-Free Homo- and Heterocoupling of Ambiphilic Tosylhydrazones to the Regioselective Triazoles and Pyrazoles. Org. Lett. 19, 1534\u20131537 (2017).","journal-title":"Org. Lett."},{"key":"54963_CR21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ejmech.2015.08.041","volume":"103","author":"NR Madadi","year":"2015","unstructured":"Madadi, N. R. et al. Synthesis and biological evaluation of novel 4,5-disubstituted 2H-1,2,3-triazoles as cis-constrained analogues of combretastatin A-4. Eur. J. Med. Chem. 103, 123\u2013132 (2015).","journal-title":"Eur. J. Med. Chem."},{"key":"54963_CR22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.tetlet.2011.10.146","volume":"53","author":"T Ponpandian","year":"2012","unstructured":"Ponpandian, T. & Muthusubramanian, S. Tandem Knoevenagel-[3+2] cycloaddition-elimination reactions: one-pot synthesis of 4,5-disubstituted 1,2,3-(NH)-triazoles. Tett. Lett. 53, 59\u201363 (2012).","journal-title":"Tett. Lett."},{"key":"54963_CR23","unstructured":"Buckman, B. O., Nicholas, J. B., Emayan, K. & Seiwert, S. D. Lysophosphatidic acid receptor antagonists. WO 2013025733 A1 (2013)."},{"key":"54963_CR24","unstructured":"Glossop, P. A. & Lane, C. A. L. Novel compounds active as muscarinic receptor antagonists. WO 2010007561 A1 (2010)."},{"key":"54963_CR25","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1021\/acsmedchemlett.6b00391","volume":"8","author":"EW Yue","year":"2017","unstructured":"Yue, E. W. et al. INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (ID01) Inhibitor for Immunooncology. Acs Med. Chem. Lett. 8, 486\u2013491 (2017).","journal-title":"Acs Med. Chem. Lett."},{"key":"54963_CR26","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.ejmech.2015.12.028","volume":"108","author":"WP Malachowski","year":"2016","unstructured":"Malachowski, W. P. et al. O-alkylhydroxylamines as rationally-designed mechanism-based inhibitors of indoleamine 2,3-dioxygenase-1. Eur. J. Med. Chem. 108, 564\u2013576 (2016).","journal-title":"Eur. J. Med. Chem."},{"key":"54963_CR27","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1021\/acsmedchemlett.6b00359","volume":"7","author":"S Panda","year":"2016","unstructured":"Panda, S., Roy, A., Deka, S. J., Trivedi, V. & Manna, D. Fused Heterocyclic Compounds as Potent Indoleamine-2,3-dioxygenase 1 Inhibitors. Acs Med. Chem. Lett. 7, 1167\u20131172 (2016).","journal-title":"Acs Med. Chem. Lett."},{"key":"54963_CR28","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1039\/C7MD00226B","volume":"8","author":"S Paul","year":"2017","unstructured":"Paul, S. et al. Synthesis and evaluation of oxindoles as promising inhibitors of the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1. Medchemcomm 8, 1640\u20131654 (2017).","journal-title":"Medchemcomm"},{"key":"54963_CR29","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejmech.2016.05.061","volume":"121","author":"S Paul","year":"2016","unstructured":"Paul, S. et al. Nitrobenzofurazan derivatives of N \u2018-hydroxyamidines as potent inhibitors of indoleamine-2,3-dioxygenase 1. Eur. J. Med. Chem. 121, 364\u2013375 (2016).","journal-title":"Eur. J. Med. Chem."},{"key":"54963_CR30","doi-asserted-by":"publisher","first-page":"5511","DOI":"10.1002\/slct.201700906","volume":"2","author":"N Pradhan","year":"2017","unstructured":"Pradhan, N. et al. Identification of Substituted 1H-Indazoles as Potent Inhibitors for Immunosuppressive Enzyme Indoleamine 2,3-Dioxygenase 1. Chemistryselect 2, 5511\u20135517 (2017).","journal-title":"Chemistryselect"},{"key":"54963_CR31","doi-asserted-by":"publisher","first-page":"7364","DOI":"10.1021\/jm900518f","volume":"52","author":"EW Yue","year":"2009","unstructured":"Yue, E. W. et al. Discovery of Potent Competitive Inhibitors of Indoleamine 2,3-Dioxygenase with in Vivo Pharmacodynamic Activity and Efficacy in a Mouse Melanoma Model. J. Med. Chem. 52, 7364\u20137367 (2009).","journal-title":"J. Med. Chem."},{"key":"54963_CR32","doi-asserted-by":"publisher","first-page":"5126","DOI":"10.1016\/j.bmcl.2010.07.025","volume":"20","author":"K Matsuno","year":"2010","unstructured":"Matsuno, K. et al. S-Benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase. Bioorganic & Medicinal Chemistry Letters 20, 5126\u20135129, https:\/\/doi.org\/10.1016\/j.bmcl.2010.07.025 (2010).","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"54963_CR33","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1021\/jm9014718","volume":"53","author":"UF Rohrig","year":"2010","unstructured":"Rohrig, U. F. et al. Rational Design of Indoleamine 2,3-Dioxygenase Inhibitors. J. Med. Chem. 53, 1172\u20131189 (2010).","journal-title":"J. Med. Chem."},{"key":"54963_CR34","doi-asserted-by":"publisher","first-page":"8321","DOI":"10.1021\/jm401195n","volume":"56","author":"SS Yang","year":"2013","unstructured":"Yang, S. S. et al. Discovery of Tryptanthrin Derivatives as Potent Inhibitors of Indoleamine 2,3-Dioxygenase with Therapeutic Activity in Lewis Lung Cancer (LLC) Tumor-Bearing Mice. J. Med. Chem. 56, 8321\u20138331 (2013).","journal-title":"J. Med. Chem."},{"key":"54963_CR35","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.1016\/j.bmc.2017.05.017","volume":"25","author":"DD Gao","year":"2017","unstructured":"Gao, D. D. & Li, Y. X. Identification and preliminary structure-activity relationships of 1-Indanone derivatives as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors. Bioorg. Med. Chem. 25, 3780\u20133791 (2017).","journal-title":"Bioorg. Med. Chem."},{"key":"54963_CR36","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1021\/ml500247w","volume":"5","author":"S Tojo","year":"2014","unstructured":"Tojo, S. et al. Crystal Structures and Structure Activity Relationships of Imidazothiazole Derivatives as IDO1 Inhibitors. Acs Med. Chem. Lett. 5, 1119\u20131123 (2014).","journal-title":"Acs Med. Chem. Lett."},{"key":"54963_CR37","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1021\/bi901546e","volume":"49","author":"AC Terentis","year":"2010","unstructured":"Terentis, A. C. et al. The Selenazal Drug Ebselen Potently Inhibits Indoleamine 2,3-Dioxygenase by Targeting Enzyme Cysteine Residues. Biochemistry 49, 591\u2013600 (2010).","journal-title":"Biochemistry"},{"key":"54963_CR38","doi-asserted-by":"publisher","first-page":"29525","DOI":"10.1074\/jbc.M301700200","volume":"278","author":"TK Littlejohn","year":"2003","unstructured":"Littlejohn, T. K., Takikawa, O., Truscott, R. J. W. & Walker, M. J. Asp(274) and His(346) are essential for heme binding and catalytic function of human indoleamine 2,3-dioxygenase. J. Biol. Chem. 278, 29525\u201329531 (2003).","journal-title":"J. Biol. Chem."},{"key":"54963_CR39","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1672-6529(09)60188-8","volume":"7","author":"S Nayar","year":"2010","unstructured":"Nayar, S., Mir, A., Ashok, A., Guha, A. & Sharma, V. Bovine Serum Albumin Binding and Drug Delivery Studies with PVA-Ferrofluid. J. Bionic. Eng. 7, 29\u201334 (2010).","journal-title":"J. Bionic. Eng."},{"key":"54963_CR40","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.bbamem.2003.12.004","volume":"1661","author":"MT Travers","year":"2004","unstructured":"Travers, M. T., Gow, I. F., Barber, M. C., Thomson, J. & Shennan, D. B. Indoleamine 2,3-dioxygenase activity and L-tryptophan transport in human breast cancer cells. Biochim. Biophys. Acta, Biomembr. 1661, 106\u2013112 (2004).","journal-title":"Biochim. Biophys. Acta, Biomembr."},{"key":"54963_CR41","first-page":"687","volume":"21","author":"GL Beatty","year":"2015","unstructured":"Beatty, G. L. & Gladney, W. L. Immune Escape Mechanisms as a Guide for Cancer Immunotherapy. Clinic. Cancer Res. 21, 687\u2013692 (2015).","journal-title":"Cancer Res."},{"key":"54963_CR42","doi-asserted-by":"publisher","first-page":"6795","DOI":"10.1158\/0008-5472.CAN-17-2285","volume":"77","author":"GC Prendergast","year":"2017","unstructured":"Prendergast, G. C., Malachowski, W. P., DuHadaway, J. B. & Muller, A. J. Discovery of IDO1 Inhibitors: From Bench to Bedside. Cancer Res. 77, 6795\u20136811 (2017).","journal-title":"Cancer Res."},{"key":"54963_CR43","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1126\/science.281.5380.1191","volume":"281","author":"DH Munn","year":"1998","unstructured":"Munn, D. H. et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281, 1191\u20131193 (1998).","journal-title":"Science"},{"key":"54963_CR44","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1099\/vir.0.053124-0","volume":"94","author":"JM Fox","year":"2013","unstructured":"Fox, J. M. et al. Inhibition of indoleamine 2,3-dioxygenase enhances the T-cell response to influenza virus infection. J. Gen. Virol. 94, 1451\u20131461 (2013).","journal-title":"J. Gen. Virol."},{"key":"54963_CR45","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.immuni.2011.07.010","volume":"35","author":"N Zhang","year":"2011","unstructured":"Zhang, N. & Bevan, M. J. CD8(+) T cells: foot soldiers of the immune system. Immunity 35, 161\u2013168 (2011).","journal-title":"Immunity"},{"key":"54963_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/srep06147","volume":"4","author":"M Srivastava","year":"2014","unstructured":"Srivastava, M. et al. Sapodilla plum (Achras sapota) induces apoptosis in cancer cell lines and inhibits tumor progression in mice. Sci. Rep. 4, 6147 (2014).","journal-title":"Sci. Rep."},{"key":"54963_CR47","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1021\/acsanm.9b00607","volume":"2","author":"A Saha","year":"2019","unstructured":"Saha, A. et al. Fatty-Amine-Conjugated Cationic Bovine Serum Albumin Nanoparticles for Target-Specific Hydrophobic Drug Delivery. ACS Appl. Nano Mater. 2, 3671\u20133683 (2019).","journal-title":"ACS Appl. Nano Mater."},{"key":"54963_CR48","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/mc.21867","volume":"52","author":"S Sharma","year":"2013","unstructured":"Sharma, S. et al. A novel DNA intercalator, 8-methoxy pyrimido[4\u2032,5\u2032:4,5]thieno (2,3-b)quinoline-4(3H)-one induces apoptosis in cancer cells, inhibits the tumor progression and enhances lifespan in mice with tumor. Mol. Carcinogen 52, 413\u2013425 (2013).","journal-title":"Mol. Carcinogen"},{"key":"54963_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.csbj.2018.11.004","volume":"17","author":"NR Maimela","year":"2019","unstructured":"Maimela, N. R., Liu, S. & Zhang, Y. Fates of CD8+ T cells in Tumor Microenvironment. Comput. struct. biotech. j. 17, 1\u201313 (2019).","journal-title":"Comput. struct. biotech. j."},{"key":"54963_CR50","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.pep.2004.06.025","volume":"37","author":"CJD Austin","year":"2004","unstructured":"Austin, C. J. D. et al. Optimised expression and purification of recombinant human indoleamine 2,3-dioxygenase. Protein Expres. Purif. 37, 392\u2013398 (2004).","journal-title":"Protein Expres. Purif."},{"key":"54963_CR51","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/S0021-9258(19)77982-4","volume":"263","author":"O Takikawa","year":"1988","unstructured":"Takikawa, O., Kuroiwa, T., Yamazaki, F. & Kido, R. Mechanism of Interferon-Gamma Action - Characterization of Indoleamine 2,3-Dioxygenase in Cultured Human-Cells Induced by Interferon-Gamma and Evaluation of the Enzyme-Mediated Tryptophan Degradation in Its Anticellular Activity. J. Biol. Chem. 263, 2041\u20132048 (1988).","journal-title":"J. Biol. Chem."},{"key":"54963_CR52","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1039\/C5MD00260E","volume":"6","author":"S Gorai","year":"2015","unstructured":"Gorai, S. et al. Inhibition of phosphatidylinositol-3,4,5-trisphosphate binding to the AKT pleckstrin homology domain by 4-amino-1,2,5-oxadiazole derivatives. Medchemcomm 6, 1798\u20131808 (2015).","journal-title":"Medchemcomm"},{"key":"54963_CR53","doi-asserted-by":"publisher","first-page":"7541","DOI":"10.1021\/jp5044305","volume":"118","author":"D Talukdar","year":"2014","unstructured":"Talukdar, D., Panda, S., Borah, R. & Manna, D. Membrane Interaction and Protein Kinase C-C1 Domain Binding Properties of 4-Hydroxy-3-(hydroxymethyl) Phenyl Ester Analogues. J. Phys. Chem. B 118, 7541\u20137553 (2014).","journal-title":"J. Phys. Chem. B"},{"key":"54963_CR54","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1016\/S0021-9258(17)35696-X","volume":"261","author":"O Takikawa","year":"1986","unstructured":"Takikawa, O., Yoshida, R., Kido, R. & Hayaishi, O. Tryptophan Degradation in Mice Initiated by Indoleamine 2,3-Dioxygenase. J. Biol. Chem. 261, 3648\u20133653 (1986).","journal-title":"J. Biol. Chem."},{"key":"54963_CR55","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/j.imbio.2015.07.014","volume":"220","author":"L Johnston","year":"2015","unstructured":"Johnston, L., Harding, S. A. & La Flamme, A. C. Comparing methods for ex vivo characterization of human monocyte phenotypes and in vitro responses. Immunobiology 220, 1305\u20131310 (2015).","journal-title":"Immunobiology"},{"key":"54963_CR56","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/cyto.a.22444","volume":"85","author":"TQ Crawford","year":"2014","unstructured":"Crawford, T. Q., Jalbert, E., Ndhlovu, L. C. & Barbour, J. D. Concomitant Evaluation of PMA plus Ionomycin-Induced Kinase Phosphorylation and Cytokine Production in T Cell Subsets by Flow Cytometry. Cytom. Part A 85, 268\u2013276 (2014).","journal-title":"Cytom. Part A"},{"key":"54963_CR57","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.tice.2018.06.003","volume":"53","author":"K Chakraborty","year":"2018","unstructured":"Chakraborty, K., Chatterjee, S. & Bhattacharyya, A. Impact of Treg on other T cell subsets in progression of fibrosis in experimental lung fibrosis. Tissue Cell 53, 87\u201392 (2018).","journal-title":"Tissue Cell"},{"key":"54963_CR58","doi-asserted-by":"crossref","unstructured":"Aziz, M. A. et al. Discovery of Potent VEGFR-2 Inhibitors based on Furopyrimidine and Thienopyrimidne Scaffolds as Cancer Targeting Agents. Sci. Rep. 6 (2016).","DOI":"10.1038\/srep24460"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-54963-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-54963-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-54963-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T11:58:03Z","timestamp":1671278283000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-54963-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,5]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["54963"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-54963-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,5]]},"assertion":[{"value":"31 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Patent has been applied for all these synthesized compounds (application No. 201731045989).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"18455"}}